ClinicalTrials.gg
RecruitingNCT05756244PREP and GOUpdated Nov 28, 2025

PRospective Evaluation of Peripartum Anticoagulation ManaGement for ThrOmboembolism

An observational study in Pregnancy Related and Venous Thromboembolism, sponsored by University of Calgary. Recruiting at 14 sites in 5 countries. Open to female participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2025-11-28.

Sponsored by University of Calgary · Observational

How we know

From the registry’s dates

  • Started Apr 2023; still recruiting 3 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
825
Ages
18 Years to 60 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 118 studies in Venous Thromboembolism with a site in Canada — 13 open to participants now, 13 under way, 8 of them phase 3. Venous Thromboembolism · Canada.

Planned enrollment
7th of 20
825 · median 605
Started
2023
with 1 other
Observational
20 of 118
1 open now
Primary completion
2029-06
later than 10 of 12 live
Registered
108th of 118
by date
Lead sponsor
5 of 118
University of Calgary

Among the 118 studies in Venous Thromboembolism with a site in Canada, this one is the 7th largest by planned enrollment of the 20 observational ones that give a count, is one of 2 that started in 2023, is one of 20 observational ones, reaches primary completion later than 10 of the 12 other live ones, and was the 108th registered.

Venous Thromboembolism

714 studies on the registry are indexed under Venous Thromboembolism; 148 are open to participants now.

Browse Venous Thromboembolism studies →

Open to participants now

13 of the 118 studies in Venous Thromboembolism with a site in Canada are open now. Recruiting first, the newest first:

7 more — sign in →

All 13 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 114 Venous Thromboembolism studies recruiting now, 91 (80%) set no upper age limit and 13 (11%) stop at 75 or younger; 9 take children under 18; 10 take healthy volunteers.

This study: 18 Years to 60 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 118 studies in Venous Thromboembolism with a site in Canada, or all of them as a file.
02

Study summary

The PREP and GO study is an international multicentre prospective cohort evaluating anticoagulation management strategies around labor and delivery and the postpartum period.

Read the detailed description

The goal of this study is to provide quality data using standardized outcome definitions on postpartum bleeding events, venous thromboembolism (VTE) risk, delivery experience outcomes and health care utilization for intrapartum and postpartum anticoagulation management among pregnant individuals on low-molecular-weight heparin (LMWH) for prevention of treatment of VTE.

03

Conditions studied

  • Pregnancy Related
  • Venous Thromboembolism
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Pregnant individuals on anticoagulation for VTE-related indications

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 years of age or older
  • Requires anticoagulation during the antepartum period of pregnancy for a VTE indication, including at least one of:

    1. Objectively confirmed VTE (DVT, superficial vein thrombosis [SVT], PE or unusual site thrombosis) diagnosed during the current pregnancy;
    2. Objectively confirmed VTE diagnosed in a prior pregnancy;
    3. Objectively confirmed VTE diagnosed when not pregnant;
    4. Inherited or acquired thrombophilia requiring anticoagulation.
  • Receiving any dose or type of LMWH during the antepartum period

Exclusion criteria

Exclusion Criteria:

  • Anticoagulation for a non-VTE indication, including prosthetic heart valves, atrial fibrillation, prevention of placenta-mediated pregnancy complications, or prevention of recurrent pregnancy loss (participants can be included with a diagnosis of antiphospholipid syndrome (APS) with or without thrombotic events)
  • Unable to provide or declined consent.
  • Home or birthing centre planned delivery.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
825 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Incidence of MB and CRNMB

    To estimate the combined incidence of major bleeding (MB) and clinically relevant non-major bleeding (CRNMB) for the six most common antepartum strategies.

    Time frame: Delivery up to 6 weeks postpartum

Secondary outcomes

  1. Practice Patterns

    To determine the practice patterns of intrapartum and postpartum anticoagulant management for pregnant individuals on LMWH for VTE indications across participating centres.

    Time frame: Prior to delivery and following delivery

  2. MB and CRNMB incidence in the immediate and 6 W postpartum period

    To estimate the incidence of MB and CRNMB in the immediate postpartum period (within 24 hours) and up to 6 weeks postpartum for each antepartum strategy.

    Time frame: Within 24 hours of delivery and up to 6 weeks postpartum

  3. MB and CRNMB incidence up to 6 W postpartum related to anticoagulation resumption

    To estimate the incidence of MB and CRNMB up to 6 weeks postpartum, based on the time and dose of postpartum anticoagulation resumption.

    Time frame: 6 weeks postpartum

  4. Incidence of VTE

    To estimate the incidence of symptomatic objectively confirmed VTE up to 6 weeks postpartum for each antepartum strategy.

    Time frame: Delivery to 6 weeks postpartum

  5. Wound Hematoma

    To estimate the incidence of wound hematoma complications up to 6 weeks postpartum for each antepartum strategy.

    Time frame: Delivery to 6 weeks postpartum

  6. Anti-Xa levels

    To compare anti-Xa levels on admission for delivery in individuals with and without immediate postpartum MB and CRNMB.

    Time frame: Delivery

  7. Hemoglobin Levels around Delivery

    To compare a change in hemoglobin levels before and after delivery in individuals with and without immediate postpartum MB and CRNMB.

    Time frame: Before and after delivery

  8. Patient Experience

    To describe delivery experience outcomes including neuraxial anesthesia (eligible vs. preferred vs. actual), patient satisfaction, and patient choice relating to delivery management options.

    Time frame: Delivery

  9. Healthcare Utilization

    To quantify healthcare utilization including hospital length of stay, postpartum length of stay, repeat procedures and induction of labor resource utilization.

    Time frame: Before and after delivery

07

Study locations

14 of 14 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Please contact study PI for requests.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2023 (actual). Primary completion is estimated for Jun 2029, 74 months after the start.

Of 97 non-industry observational studies under Venous Thromboembolism, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 86. This study's planned 74 months is above that.

Counting every sponsor, half of 118 studies reached it within 45 months; a quarter within 23 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 21, 2023
First posted
Mar 6, 2023
StartActual
Apr 4, 2023
Primary completionEst.
Jun 30, 2029
CompletionEst.
Dec 31, 2029
Last update
Nov 28, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 28, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05756244
Responsible party
Sponsor
First posted
Mar 6, 2023
Start date
Apr 4, 2023
Primary completion
Jun 30, 2029 (estimated)
Completion
Dec 31, 2029 (estimated)
Last update
Nov 28, 2025

Study contacts

Jill Baxter, BSc
Contact
jbaxter@ucalgary.ca
403-220-7103
Leslie Skeith, MD
Contact
laskeith@ucalgary.ca
403-944-5246
Leslie Skeith, MD
principal investigator · University of Calgary
Isabelle Malhamé, MD
principal investigator · McGill University
Kinga Malinowski, MD
principal investigator · University of Toronto

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion